Name
L-VAM
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for L-VAM
Name
Alternate Names
Ametycine
Mito-Medac
Mitocin
Mitocin-C
MitoExtra
Mitomycin-C
Mitomycin-X
Mutamycin
Mutamycine
Abbreviations
MITC
Mito
MITO-C
MMC
MTC
Category
Chemotherapy
Subcategory
Alkylating agent
Antibiotic
NSC Number
26980
026980
Primary Site
Breast
Cervical cancer
Gastric cancer
Non-small cell lung cancer (NSCLC)
Pancreatic cancer
Superficial bladder cancer
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Abbott-43818
Carcinil
Eligard
Leuprolide
Leuprorelin
Lupron
Lupron Depot
Lupron TAP
TAP-144
Viadur
Abbreviations
None
Category
Hormones and hormonal mechanisms
Subcategory
Gonadotropin-releasing hormone agonist
NSC Number
377526
Primary Site
Histology
None
Remarks
December 2016 Update: Lupron as ovarian suppressor in pre-menopausal breast cancer has been approved by the FDA per NCI. Beginning with cases diagnosed 1/1/2017 forward, code as hormone therapy.
Lupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.
FOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment
FOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017:
The effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used "off label" for other conditions. Lupron should be coded as "Other Therapy" until such time that it receives FDA approval.
Lupron is a gonadotropin-releasing hormone analogue. FDA approved its use on prostate cancer and should be coded as hormone therapy.
FOR BREAST CASES DIAGNOSED 1/1/2017 FORWARD: Code as hormone treatment
FOR BREAST CASES DIAGNOSED PRIOR TO 1/1/2017:
The effectiveness of Lupron on patients with breast cancer was being studied in one clinical trial. This trial was looking at extended endocrine therapy for pre-menopausal women with breast cancer. This trial is looking at the drug combination of letrozole and leuprolide for women who have taken Tamoxifen for at least 4-5 years. This drug combination is used in the treatment for metastatic breast cancer and is sometimes used for treatment of early stage breast cancer. However, as of early December 2016 it has not been accepted as a standard of care treatment and had not yet received FDA approval for treatment of breast cancer. While it may not have received FDA approval, it can be used "off label" for other conditions. Lupron should be coded as "Other Therapy" until such time that it receives FDA approval.
Coding
Please see remarks for additional information
Name
Alternate Names
14-hydroxy-daunomycin
Adri-blastina (Italy)
Adriamycin
Adriamycin-TM
Caelyx
FT-106
Hydroxydaunomycin
Myocet
Pegylated Liposomal Doxorubicin Hcl
Rubex
S-DOX
Stealth(R) Liposomal Doxorubicin
Abbreviations
ADM
ADR
ADRI
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
123127
Primary Site
Histology
None
Remarks
Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic
Coding
This drug should be coded
Name
Alternate Names
29060-LE
Alkaban
LE-29060
Velban
Velbe
Velsar
Vinblastine
Vinblastine sulfate
Abbreviations
VBL
VELB
VLB
Category
Chemotherapy
Subcategory
Plant alkaloid
NSC Number
049842
49842
Primary Site
None
Histology
None
Remarks
A cell cycle specific chemotherapeutic agent; vinca plant alkaloid; mitotic inhibitor. FDA approved uses in 3rd line breast cancer, choriocarcinoma, palliative in stages III and IV Hodgkin's lymphoma, Kaposi's sarcoma, mycosis fungoides, palliative in non-Hodgkin's histiocytic/lymphocytic lymphoma, and advanced testicular carcinoma.
Coding
This drug should be coded